Biopsy verification technology developer Strand Diagnostics had raised $7.5m of a commitment from Nantworks originally slated to reach $30m.

Laboratory network operator P4 Diagnostix has paid an undisclosed amount for the assets of Strand Diagnostics, a US-based DNA testing services provider backed by diversified technology development group NantWorks.

Formed in 2012 through the merger of Strand Analytical Laboratories and Diagnostic ID, Strand Diagnostics has created a technology system that relies on barcoding to verify the quality of biopsy samples and ensure they are allocated to the correct patient.

The tests are offered in variants for breast and advanced prostate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?